Natus Medical buys Excel-Tech
This article was originally published in The Gray Sheet
Executive Summary
Neurodiagnostics firm Natus Medical acquires Excel-Tech for $63.6 million, gaining the latter firm's electrodiagnostic systems and disposables for the detection, diagnosis and monitoring of neurologic disorders, including central and peripheral nervous system dysfunction, as well as sleep disorders. Announced Oct. 10, the deal bolsters Natus' neurology offerings and adds $33.4 million in annual sales, furthering Natus' goal of achieving annual sales of $250 million by the end of 2008, according to the firm. Natus' product offerings include systems for screening, detection, treatment, monitoring and tracking of neurological dysfunction, epilepsy, sleep disorders, hearing impairment and newborn care. Under the terms of the deal, Natus is paying $3.34 per share for Toronto-based Excel-Tech, a roughly 82% premium over its Oct. 9 closing price of $1.84. The deal will be immediately accretive to Natus earnings, excluding one-time charges
You may also be interested in...
Cool-Cap hits the market
Natus Medical subsidiary Olympic Medical receives FDA approval Feb. 11 to begin U.S. shipments of its Cool-Cap device to treat hypoxic ischemic encephalopathy in newborns, and expects to fulfill most of its backlog orders by the end of the first quarter. Cool-Cap, which lowers body temperature to reduce brain swelling, was FDA-approved in December 2006, but required PMA-supplements for component updates before it could be sold commercially. Separately, Natus launched a restructuring plan to be phased in during the first nine months of 2008 to improve operating efficiency after recent acquisitions, including the November 2007 purchase of Xltek (1"The Gray Sheet" Oct. 15, 2007, In Brief). Natus will cut its North American field sales and service force, and continue to outsource assemblies to contract manufacturers, the firm said Feb. 11. The plan is expected to save $2.4 million in 2009
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.